Replies to post #224125 on Biotech Values

[DewDiligence]

ARPO—(+19%/AH)—climbs on the COVID-19 bandwagon:

https://finance.yahoo.com/news/aerpio-pharmaceuticals-inc-quantum-leap-203010639.html

Why not? ARPO is a diabetes company, and T2D supposedly elevates the risk in COVID-19 infection.

(I’m being facetious.)